Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Ultra High-Frequency Ultrasound and Photoacoustics Enable Breakthrough Molecular Imaging in Translational Research

Abstract:
Designed specifically for preclinical research, ultra high-frequency ultrasound systems enable in vivo viewing and assessment of miniscule targets. When combined with high-resolution molecular imaging, these systems allow researchers to view small-animal anatomical structures and micro-environmental functions in real time, such as beating hearts and growing malignancies.

Ultra High-Frequency Ultrasound and Photoacoustics Enable Breakthrough Molecular Imaging in Translational Research

Toronto, Canada | Posted on September 3rd, 2012

This breakthrough ultrasound technology allows the world's most prestigious pharmaceutical and biotechnology companies, hospitals, and universities to enhance their research capabilities in areas such as translational research, cardiovascular function and disease, cancer, neurobiology, developmental biology, drug development, phenotypic studies, and genetic research, among others.

One company that has established itself as a leader in preclinical, in vivo imaging is VisualSonics, Inc., a wholly owned subsidiary of clinical ultrasound manufacturer SonoSite, Inc., a Fujifilm company. VisualSonics' Vevo® products line includes high-frequency micro-imaging systems (Vevo® 2100 and 770) and a premier photoacoustic imaging platform, the Vevo LAZR*. The Vevo LAZR* has expanded in vivo nanoparticle imaging and microenvironmental research capabilities by simultaneously collecting and displaying high-resolution micro-ultrasound and photoacoustic signals. These systems have found strong utility in advanced preclinical research resulting in over 700 peer-reviewed publications across the globe.

One area where these technologies show particular promise is translational research. Because translational research connects preclinical research at the bench with clinical outcomes at the patients' bedside, the development of research tools that promise and show direct relevance to imaging and quantification of diseases in humans is critical for today's basic science researchers. As the primary and secondary causes of death globally, cardiovascular disease and cancer represent important basic research and clinical research areas, which can be studied in animal models non-invasively in real-time through the use of high-frequency ultrasound. And, using the company's photoacoustic technology for molecular imaging, cancer can be studied in its earliest stages of progression in animal test subjects.


To introduce in vivo high-frequency ultrasound and photoacoustic imaging to researchers and other potential users, VisualSonics has been offering lab visits with top preclinical researchers using these advanced technologies, as well as free webinar presentations by some of the world's most respected authorities on high-resolution micro-imaging.

To register for upcoming webinars, demonstrations, and laboratory visits—or to learn more about ultra high-frequency ultrasound and molecular imaging systems—go to: VisualSonics.com

####

For more information, please click here

Contacts:
3080 Yonge Street Suite 6100, Box 66
Toronto, Ontario, Canada
M4N 3N1
T. +1.416.484.5000
F. +1.416.484.5001
North American Toll Free 1.866.416.4636

SA Perillo

Copyright © VisualSonics Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Tools

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanometrics Announces $50 Million Share Repurchase Program November 15th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

Oxford Instruments announces winner of the 2017 Sir Martin Wood Prize for Japan November 14th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project